Zydus Lifesciences gets USFDA nod to begin Phase II clinical trial of ZYIL1 in Parkinson's disease patients
Zydus has been granted an 'Orphan Drug Designation' by the US FDA for ZYIL1 in treatment of patients with CAPS, a rare auto-inflammatory disease.;
Ahmedabad: Zydus Lifesciences Limited, a discovery-based, global pharmaceutical company, has announced that it has received permission from USFDA, to initiate the Phase II clinical study of NLRP3 inhibitor “ZYIL1” in patients with Parkinson’s disease.
Parkinson’s is a devastating disease with patients steadily losing the control on movements leading to unintended or uncontrollable movements, such as shaking, stiffness and difficulty with balance and co-ordination. It is estimated that there are more than 8.5 mn people in the world suffering from Parkinson’s disease, with 1 mn suffering from the disease in the US. Each year 90,000 new cases of Parkinson’s disease are reported in the US. Analysts estimate that the treatment costs of Parkinson’s disease amounts to almost U.S. $52 billion every year, and by 2037 this disease is estimated to touch U.S. $80 billion every year.
Speaking on the development Pankaj R. Patel, Chairman, Zydus Lifesciences Ltd. said, “Our researchers have been working on path-breaking discoveries that can unlock new possibilities and help patients lead more healthier and fulfilled lives. Our team is developing a novel, disease modifying approach through inhibiting the activation of NLRP3 inflammasome with ZYIL1, which could potentially reduce neuroinflammation and neuro-degeneration in patients suffering from Parkinson’s disease.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.